Our Take
Biotech teams chase upstream titer gains while ignoring the scale realities that wreck purification timelines and cost; this webinar names the five concrete oversights that cause that divergence.
Why it matters
As monoclonal antibody titers rise and novel modalities multiply, early design mistakes force expensive reactive workarounds at scale. Getting purification design right during MSAT and tech transfer prevents deviations, safety risks, and cycle-time slips later.
Do this week
Process lead: audit your raw material supply chain, buffer formulations, and single-use consumable specs against scale-ready failure modes before your next MSAT readout.
Five Common Design Gaps That Stall Purification at Scale
GEN is hosting a webinar focused on five specific planning failures that create downstream bottlenecks in therapeutic bioprocessing. The gaps include single-source material dependency, suboptimal raw material pack size selection, buffer designs that fail under stress, and single-use systems specified without realistic failure scenarios.
The webinar will use real-world MSAT (manufacturability, scale-up, analytical, and tech transfer) examples and tech transfer case studies to show how each gap cascades into deviations, safety risks, and longer purification cycle times. Speakers will walk through practical strategies for evaluating materials, buffer systems, and consumables through a scale-ready lens.
Upstream Titer Gains Fall Apart Without Downstream Planning
Biotech teams routinely optimize upstream expression to increase titer, then discover during scale-up that purification infrastructure cannot keep pace. Single-source material dependency creates supply bottlenecks. Wrong pack sizes force process changes mid-run. Sensitive buffers fail reproducibly at manufacturing scale. Single-use systems chosen for convenience rather than failure modes introduce unexpected downtime.
These oversights are not new, but rising titer and increasing modality complexity amplify their impact. Monoclonal antibody programs face pressure to scale fast; novel modalities add purification complexity on top. Teams that ignore purification design until MSAT or tech transfer force reactive workarounds that degrade throughput, spike costs, and risk quality.
How to Audit Your Process Design Before Scale
The webinar offers a structured review approach. Evaluate whether your raw material sourcing relies on a single vendor (yes = risk). Check whether your buffer packs are sized for realistic batch volumes and failure scenarios, not theoretical minimums. Review your single-use system specifications: do they account for pressure surges, temperature fluctuations, or contamination events? Test your designs against manufacturing variability, not just lab conditions.
The live Q&A with expert panelists provides a chance to pressure-test your own process gaps. If your team is planning MSAT or has tech transfer on the horizon, this webinar addresses the five failure modes most likely to force schedule slip and rework.